Amryt Pharma
AMYT
AMYT was delisted on the 11th of April, 2023.
34 hedge funds and large institutions have $185M invested in Amryt Pharma in 2021 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 6 closing their positions.
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
25% more capital inflows, than outflows
Capital inflows: $14.3M | Capital outflows: $11.4M
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
17% more funds holding
Funds holding: 29 → 34 (+5)
0.45% more ownership
Funds ownership: 23.42% → 23.88% (+0.45%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$4.22M |
| 2 |
Stonepine Capital Management
Bend,
Oregon
|
+$3.4M |
| 3 |
GFI
Global Frontier Investments
Charleston,
South Carolina
|
+$2.36M |
| 4 |
Armistice Capital
New York
|
+$1.69M |
| 5 |
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
+$552K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Highbridge Capital Management
New York
|
-$4.21M |
| 2 |
Whitebox Advisors
Minneapolis,
Minnesota
|
-$3.7M |
| 3 |
Monashee Investment Management
Boston,
Massachusetts
|
-$2.79M |
| 4 |
Nexpoint Asset Management
Dallas,
Texas
|
-$496K |
| 5 |
EdgePoint Investment Group
Toronto,
Ontario, Canada
|
-$176K |
AMYT Hedge Fund Activity: Q2 2021 in Review
34 of the 5,771 institutional investors tracked by Wall St. Rank reported a position in Amryt Pharma (AMYT) for Q2 2021, worth a combined $185M — down 11% from $209M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new AMYT positions and 6 closed out — a net gain of 5 holders — while 9 added to existing stakes and 4 trimmed.
The largest buyer was Aquilo Capital Management, adding an estimated $4.22M. The largest seller was Highbridge Capital Management, cutting an estimated $4.21M.
- 34 institutional investors held Amryt Pharma (AMYT) as of Q2 2021, up from 29 in Q1 2021.
- Funds reported $185M of Amryt Pharma stock for Q2 2021, down 11% quarter-over-quarter.
- 11 funds opened new Amryt Pharma positions in Q2 2021 and 6 closed out, a net change of +5 holders.
- The largest Amryt Pharma buyer in Q2 2021 was Aquilo Capital Management, an estimated $4.22M added.
- The largest Amryt Pharma seller in Q2 2021 was Highbridge Capital Management, an estimated $4.21M sold.
Based on aggregated 13F filings for Q2 2021.